Development and evaluation of AS03, an Adjuvant System containing α-tocopherol and squalene in an oil-in-water emulsion

Expert Review of Vaccines

Volumn 11, Issue 3, 2012, Pages 349-366

  Garçon, Nathalie ^a   Vaughn, David W ^a   Didierlaurent, Arnaud M ^a  

^a GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

Author keywords

tocopherol; Adjuvant System; AS03; immunostimulant; influenza; oil in water emulsion; pandemic; prepandemic; vaccine

Indexed keywords

ADJUVANT; ALPHA TOCOPHEROL; ANTIGEN; HEMAGGLUTININ; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INFLUENZA VACCINE; MALARIA VACCINE; POLYSORBATE 80; SIALIDASE; SQUALENE; WATER OIL CREAM;

DRUG EFFICACY; DRUG SAFETY; FATIGUE; HUMAN; HUMORAL IMMUNITY; IMMUNOGENICITY; INFLUENZA VACCINATION; INFLUENZA VIRUS A H5N1; INJECTION SITE PAIN; INNATE IMMUNITY; LYMPH NODE; MALARIA FALCIPARUM; MYALGIA; NONHUMAN; PRIORITY JOURNAL; REVIEW; VIRUS REPLICATION;

ADJUVANTS, IMMUNOLOGIC; ALPHA-TOCOPHEROL; ANIMALS; ANTIGENS; DRUG COMBINATIONS; EMULSIONS; HUMANS; INFLUENZA VACCINES; OILS; POLYSORBATES; SQUALENE; WATER;

EID: 84859020840     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.11.192     Document Type: Review

References (109)

1. Baras B, Stittelaar KJ, Simon JH et al. Cross-protection against lethal H5N1 challenge in ferrets withan adjuvanted pandemic influenza vaccine. PLoS ONE 3(1), e1401 (2008). This preclinical study demonstrates the importance of AS03 to obtain crossprotection in a lethal influenza model.
2. Edelman R. Vaccine adjuvants. Rev. Infect. Dis. 2(3), 370-383 (1980).
3. Ott G, Barchfeld GL, Chernoff D, Radhakrishnan R, van Hoogevest P, van Nest G. MF59. Design and evaluation of a safe and potent adjuvant for human vaccines. Pharm. Biotechnol. 6, 277-296 (1995).
4. Schultze V, D'Agosto V, Wack A, Novicki D, Zorn J, Hennig R. Safety of MF59TM adjuvant. Vaccine 26(26), 3209-3222 (2008).
5. Pellegrini M, Nicolay U, Lindert K, Groth N, Della CG. MF59-adjuvanted versus non-adjuvanted influenza vaccines: integrated analysis from a large safety database. Vaccine 27(49), 6959-6965 (2009).
6. Brigelius-Flohé R, Traber MG. Vitamin E:function and metabolism. FASEB J. 13(10), 1145-1155 (1999).
7. Burton GW, Traber MG, Acuff RV et al. Human plasma and tissue alpha-tocopherol concentrations in response to supplementation withdeuterated natural and synthetic vitamin E. Am. J. Clin. Nutr. 67(4), 669-684 (1998).
8. Traber MG, Atkinson J. Vitamin E,antioxidant and nothing more. Free Radic. Biol. Med. 43(1), 4-15 (2007).
9. Azzi A, Gysin R, Kempná P et al. Regulation of gene expression by alpha-tocopherol. Biol. Chem. 385(7), 585-591 (2004).
10. Zingg J-M. Modulation of signal transduction by vitamin E. Mol. Aspects Med. 28(5-6), 481-506 (2007).
11. Wu D, Meydani SN. Age-associated changes inimmune and inflammatory responses: impact of vitamin E intervention. J. Leukoc. Biol. 84(4), 900-914 (2008).
12. De la Fuente M, Hernanz A, Guayerbas N, Victor VM, Arnalich F. Vitamin Eingestion improves several immune functions in elderly men and women. Free Radic. Res. 42(3), 272-280 (2008).
13. Franchini A, Bertuzzi S, Tosarelli C, Manfreda G. Vitamin Ein viral inactivated vaccines. Poult. Sci. 74(4), 666-671 (1995).
14. Afzal M, Tengerdy RP, Ellis RP, Kimberling CV, Morris CJ. Protection of rams against epididymitis by a Brucella ovis-vitamin E adjuvant vaccine. Vet. Immunol. Immunopathol. 7(3-4), 293-304 (1984).
15. Tengerdy RP, Ameghino E, Riemann H. Serological responses of rams to a Brucella ovis-vitamin E adjuvant vaccine. Vaccine 9(4), 273-276 (1991).
16. Tengerdy RP, Lacetera NG. Vitamin Eadjuvant formulations in mice. Vaccine 9(3), 204-206 (1991).
17. Do R, Kiss RS, Gaudet D, Engert JC. Squalene synthase: acritical enzyme in the cholesterol biosynthesis pathway. Clin. Genet. 75(1), 19-29 (2009).
18. Charlton-Menys V, Durrington PN. Human cholesterol metabolism and therapeutic molecules. Exp. Physiol. 93(1), 27-42 (2008).
19. Liu GCK, Ahrens EH Jr, Schreibman PH, Crouse JR. Measurement of squalene in human tissues and plasma: validation and application. J. Lipid Res. 17(1), 38-45 (1976).
20. Nikkari T, Schreibman PH, Ahrens EH Jr.In vivo studies of sterol and squalene secretion by human skin. J. Lipid Res. 15(6), 563-573 (1974).
21. Huang ZR, Lin YK, Fang JY. Biological and pharmacological activities of squalene and related compounds: potential uses in cosmetic dermatology. Molecules 14(1), 540-554 (2009).
22. Reddy LH, Couvreur P. Squalene: anatural triterpene for use in disease management and therapy. Adv. Drug Deliv. Rev. 61(15), 1412-1426 (2009).
23. Nema S, Washkuhn RJ, Brendel RJ. Excipients and their use in injectable products. PDA J. Pharm. Sci. Technol. 51(4), 166-171 (1997).
24. Stoute JA, Slaoui M, Heppner DG et al. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. N. Engl. J. Med. 336(2), 86-91 (1997). This study is the first demonstration in human volunteers of the efficacy of RTS, S/AS02 vaccination against homologous Plasmodium falciparum sporozoite challenge in a laboratory setting.
25. Stoute JA, Kester KE, Krzych U et al. Long-term efficacy and immune responses following immunization withthe RTS,S malaria vaccine. J. Infect. Dis. 178(4), 1139-1144 (1998).
26. + T cells producing IFN-γ. J. Immunol. 171(12), 6961-6967 (2003).
27. McElrathMJ, Haynes BF.Induction of immunity to human immunodeficiency virus type-1 by vaccination. Immunity 33(4), 542-554 (2010).
28. Li Y, Svehla K, Mathy NL, Voss G, Mascola JR, Wyatt R. Characterization of antibody responses elicited by human immunodeficiency virus type 1 primary isolate trimeric and monomeric envelope glycoproteins in selected adjuvants. J. Virol. 80(3), 1414-1426 (2006).
29. The rgp120 HIV Vaccine Study Group. Placebo-controlled Phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J. Infect. Dis. 191(5), 654-665 (2005).
30. Kuehn BM. CDC advisory committee recommends nearly universal influenza vaccination. JAMA 303(12), 1136 (2010).
31. Sander B, Kwong JC, Bauch CT et al. Economic appraisal of Ontario's Universal Influenza Immunization Program: a cost-utility analysis. PLoS Med. 7(4), e1000256 (2010).
32. Johnson NPAS, Mueller J. Updating the accounts: global mortality of the 1918-1920 "Spanish" influenza pandemic. Bull. Hist. Med. 76(1), 105-115 (2002).
33. Webster RG, Govorkova EA. H5N1 influenza -continuing evolution and spread. N. Engl. J. Med. 355(21), 2174-2177 (2006).
34. Rimmelzwaan GF, McElhaney JE. Correlates of protection: novel generations of influenza vaccines. Vaccine 26(Suppl. 4), D41-D44 (2008).
35. Hannoun C, Megas F, Piercy J. Immunogenicity and protective efficacy of influenza vaccination. Virus Res. 103(1-2), 133-138 (2004).
36. Beyer WEP, Palache AM, Baljet M, Masurel N. Antibody induction byinfluenza vaccines in the elderly: a review of the literature. Vaccine 7(5), 385-394 (1989).
37. Johansson BE, Cox MM. Influenza viral neuraminidase: the forgotten antigen. Expert. Rev. Vaccines 10(12), 1683-1695 (2011).
38. Jegerlehner A, Schmitz N, Storni T, Bachmann MF. Influenza Avaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity. J. Immunol. 172(9), 5598-5605 (2004).
39. Mozdzanowska K, Maiese K, Gerhard W. thcell-deficient mice control influenza virus infection more effectively than th- and B cell-deficient mice: evidence for a th-independent contribution by B cells to virus clearance. J. Immunol. 164(5), 2635-2643 (2000).
40. + T cells in protective immunity to influenza. Immunol. Rev. 211 8-22 (2006).
41. Kreijtz JH, Fouchier RA, Rimmelzwaan GF. Immune responses toinfluenza virus infection. Virus Res. 162(1-2), 19-30 (2011).
42. Treanor JJ, Campbell JD, Zangwill KM, Rowe T, Wolff M. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N. Engl. J. Med. 354(13), 1343-1351 (2006).
43. Bresson J-L, Perronne C, Launay O et al. Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: Phase I randomised trial. Lancet 367(9523), 1657-1664 (2006).
44. Ehrlich HJ, Müller M, Oh HML et al. A clinical trial of a whole-virus H5N1 vaccine derived from cell culture. N. Engl. J. Med. 358(24), 2573-2584 (2008).
45. Khurana S, Chearwae W, Castellino F et al. Vaccines withMF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5N1 influenza virus. Sci. Transl. Med. 2(15), 15ra5 (2010).
46. Langley JM, Frenette L, Ferguson L et al. Safety and cross-reactive immunogenicity of candidate AS03-adjuvanted prepandemic H5N1 influenza vaccines: a randomized controlled Phase 1/2 trial in adults. J. Infect. Dis. 201(11), 1644-1653 (2010). This study demonstrates that adjuvants can impact on the quality of the antigenspecific antibody repertoire in humans.
47. Hampson AW. Ferrets and the challenges of H5N1 vaccine formulation. J. Infect. Dis. 194(2), 143-145 (2006).
48. Baras B, Jacob V, Mossman SP, Wettendorf MA. Immunogenicity of adjuvanted split H5N1 pandemic vaccine in mice. Presented at: Options for the Control of Influenza VI. Toronto, Canada, 17-23 June 2007.
49. Baras B, Stittelaar KJ, Simon JH et al. Immunization withlow-dose adjuvanted split H5N1 pandemic vaccine protects ferrets against homologous challenge. Presented at: Options for the Control of Influenza VI. Toronto, Canada, 17-23 June 2007.
50. A-adjuvanted split H5N1 vaccine in ferrets. Vaccine 29(11), 2092-2099 (2011). This nonclinical study demonstrates that two doses of AS03-adjuvanted H5N1 vaccine are preferable to obtain high and sustainable immune responses.
51. Mallet C, Baras B, Mossman S et al. Intramuscular immunization withlow dose adjuvanted detergent-split H5N1 influenza vaccine protects ferrets against intratracheal challenge withwild-type homologous virus. Presented at: The Third European Influenza Conference. Vilamoura, Portugal, 14-17 September 2008.
52. Mallet C, Baras B, Mossman SP et al. Immunization withlow-dose adjuvanted split H5N1/Indonesia/5/2005 vaccine protects ferrets against challenge with wild-type heterosubtypic H5N1 A/Hong-Kong/156/1997 virus. Presented at: 11th International Symposium on Respiratory Viral Infections. Bangkok, thailand, 19-22 February 2009.
53. Leroux-Roels I, Borkowski A, Vanwolleghem T et al. Antigen sparing and cross-reactive immunity withan adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet 370(9587), 580-589 (2007). This study is a demonstration in a clinical setting that using AS03 allows antigen sparing.
54. A-adjuvanted prepandemic influenza vaccine: a Phase III study in a large population of Asian adults. Vaccine 27(52), 7428-7435 (2009).
55. Langley JM, Risi G, Caldwell M et al. Dose-sparing H5N1 A/Indonesia/05/2005 pre-pandemic influenza vaccine in adults and elderly adults: a Phase III, placebo-controlled, randomized study. J. Infect. Dis. 203(12), 1729-1738 (2011).
56. A-adjuvanted vaccination in adults. J. Infect. Dis. 204(4), 574-581 (2011).
57. Schwarz TF, Horacek T, Knuf M et al. Single dose vaccination withAS03-adjuvanted H5N1 vaccines in a randomized trial induces strong and broad immune responsiveness to booster vaccination in adults. Vaccine 27(45), 6284-6290 (2009).
58. Schwarz TF, Horacek T, Knuf M, Damman H-G, Gillard P, Jilg W. Single-dose primary vaccination with AS03A-adjuvanted prepandemic H5N1 influenza vaccine is sufficient to induce strong, rapid and broad immune response to booster vaccination after 12 months. Presented at: 3rd Annual Global Vaccine Congress. Singapore, 4 October 2009.
59. Heijmans S, De Meulemeester M, Reynders P et al. AS03-adjuvanted prepandemic influenza vaccine: high immunogenicity in the Elderly. Presented at: 2nd Vaccine Global Congress. Boston, MA, USA, 7-9 December 2008.
60. Viboud C, Boëlle P-Y, Cauchemez S et al. Risk factors of influenza transmission in households. Br. J. Gen. Pract. 54(506), 684-689 (2004).
61. Díez-Domingo J, Garcés-Sanchez M, Baldó J-M et al. Immunogenicity and safety of H5N1 A/Vietnam/1194/2004 (Clade 1) AS03-adjuvanted prepandemic candidate influenza vaccines in children aged 3 to 9 years. A Phase II, randomized, open, controlled study. Pediatr. Infect. Dis. J. 29(6), e35-e46 (2010).
62. Leroux-Roels I, Bernhard R, Gérard P, Dramé M, Hanon E, Leroux-Roels G. Broad Clade 2 cross-reactive immunity induced by an adjuvanted clade 1 rH5N1 pandemic influenza vaccine. PLoS ONE 3(2), e1665 (2008). This study is a demonstration in a clinical setting that using AS03 induces cross-immunity in the context of H5N1 pandemic vaccine.
63. Fragapane E, Gasparini R, Schioppa F, Laghi-Pasini F, Montomoli E, Banzhoff A. A heterologous MF59-adjuvanted H5N1 prepandemic influenza booster vaccine induces a robust, cross-reactive immune response in adults and the elderly. Clin. Vaccine Immunol. 17(11), 1817-1819 (2010).
64. Stephenson I, Bugarini R, Nicholson KG et al. Cross-reactivity tohighly pathogenic avian influenza H5N1 viruses after vaccination withnonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a potential priming strategy. J. Infect. Dis. 191(8), 1210-1215 (2005).
65. A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study. Vaccine 28(3), 849-857 (2010).
66. Risi G, Frenette L, Langley JM et al. Immunological priming induced bya two-dose series of H5N1 influenza antigen, administered alone or in combination with two different formulations of AS03 adjuvant in adults: results of a randomised single heterologous booster dose study at 15 months. Vaccine 29(37), 6408-6418 (2011).
67. A induces strong cross-reactive and polyfunctional CD4 T-cell responses. J. Clin. Immunol. 31(3), 443-454 (2011). This study is a demonstration in a clinical study of the activating effect of AS03 on cell-mediated immunity.
68. Greenberg ME, Lai MH, Hartel GF et al. Response to amonovalent 2009 influenza A (H1N1) vaccine. N. Engl. J. Med. 361(25), 2405-2413 (2009).
69. A-adjuvant: preliminary report of an observer-blind, randomised trial. Vaccine 28(7), 1740-1745 (2010).
70. Baras B, de Waal L, Stittelaar KJ et al. Pandemic H1N1 vaccine requires the use of an adjuvant to protect against challenge in naive ferrets. Vaccine 29(11), 2120-2126 (2011).
71. Madhun AS, Akselsen PE, Sjursen H et al. An adjuvanted pandemic influenza H1N1 vaccine provides early and long term protection in healthcare workers. Vaccine 29(2), 266-273 (2010).
72. A-adjuvanted influenza A(H1N1) 2009 vaccine for adults up to 85 years of age. Clin. Infect. Dis. 51(6), 668-677 (2010).
73. Huijskens E, Rossen J, Mulder P et al. Immunogenicity, boostability, and sustainability of the immune response after vaccination against Influenza A virus (H1N1) 2009 in a healthy population. Clin. Vaccine Immunol. 18(9), 1401-1405 (2011).
74. Cox CM, Blanton L, Dhara R, Brammer L, Finelli L. 2009 Pandemic influenza A(H1N1) deaths among children - United States, 2009-2010. Clin. Infect. Dis. 52(Suppl. 1), S69-S74 (2011).
75. Miller E, Hoschler K, Hardelid P, Stanford E, Andrews N, Zambon M. Incidence of 2009 pandemic influenza A H1N1 infection in England: a cross-sectional serological study. Lancet 375(9720), 1100-1108 (2010).
76. Badjuvanted split virion versus nonadjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: open label, randomised, parallel group, multicentre study. BMJ 340, c2649 (2010). This study is the first direct comparison of an AS03-adjuvanted split influenza vaccine witha nonadjuvanted whole virion formulation in children.
77. Carmona A, Omeñaca F, Tejedor JC et al. Immunogenicity and safety of AS03-adjuvanted 2009 influenza A H1N1 vaccine in children 6-35 months. Vaccine 28(36), 5837-5844 (2010).
78. Langley JM, Reich D, Aggarwal N et al. Immunogenicity and safety of an A/H1N1v 2009 pandemic influenza vaccine formulated withand without AS03 adjuvant in children aged 6 months to less than 9 years. Presented at: Options for the Control of Influenza VII. Hong-Kong, SAR, China, 3-7 September 2010.
79. Ho J, Moir S, Wang W et al. Enhancing effects of adjuvanted 2009 pandemic H1N1 influenza A vaccine on memory B-cell responses in HIV-infected individuals. AIDS 25(3), 295-302 (2011).
80. Roman F, Clément F, Dewé W et al. Effect oncellular and humoral immune responses of the AS03 Adjuvant System in an A/H1N1/2009 influenza virus vaccine administered to adults during two randomized controlled trials. Clin. Vaccine Immunol. 18(5), 835-843 (2011).
81. Hardelid P, Fleming DM, McMenamin J et al. Effectiveness of pandemic and seasonal influenza vaccine in preventing pandemic influenza A(H1N1)2009 infection in England and Scotland 2009-2010. Euro. Surveill. 16(2), Article 3 (2011).
82. Örtqvist Å, Berggren I, Insulander M, de Jong B, Svenungsson B. Effectiveness of an adjuvanted monovalent vaccine against the 2009 pandemic strain of influenza A(H1N1)v in Stockholm County, Sweden. Clin. Infect. Dis. 52(10), 1203-1211 (2011).
83. Pelat C, Falchi A, Carrat F et al. Field effectiveness of pandemic and 2009-2010 seasonal vaccines against 2009-2010 A(H1N1) influenza: estimations from surveillance data in France. PLoS ONE 6(5), e19621 (2011).
84. Puig-Barberà J, Arnedo-Pena A, Pardo- Serrano F et al. Effectiveness of seasonal 2008-2009, 2009-2010 and pandemic vaccines, to prevent influenza hospitalizations during the autumn 2009 influenza pandemic wave in Castellón, Spain. A test-negative, hospital-based, case-control study. Vaccine 28(47), 7460-7467 (2010).
85. Simpson CR, Ritchie LD, Robertson C, Sheikh A, McMenamin J. Vaccine effectiveness inpandemic influenza - primary care reporting (VIPER): an observational study to assess the effectiveness of the pandemic influenza A (H1N1)v vaccine. HealthTechnol. Assess. 14(34), 313-346 (2010).
86. Skowronski DM, Janjua NZ, De Serres G et al. Effectiveness of AS03 adjuvanted pandemic H1N1 vaccine: case-control evaluation based on sentinel surveillance system in Canada, autumn 2009. BMJ 342, c7297 (2011).
87. Valenciano M, Kissling E, Cohen J-M et al. Estimates of pandemic influenza vaccine effectiveness in Europe, 2009-2010: results of influenza monitoring vaccine effectiveness in Europe (I-MOVE) multicentre case-control study. PLoS Med. 8(1), e1000388 (2011).
88. Wichmann O, Stöcker P, Poggensee G et al. Pandemic influenza A(H1N1) 2009 breakthrough infections and estimates of vaccine effectiveness in Germany 2009-2010. Euro. Surveill. 15(18), 1 (2010).
89. Hamrin J, Bennet R, Eriksson M, Lind G, Örtqvist E. Effectiveness of a mono-valent adjuvanted vaccine (Pandemrix) for the prevention of hospitalisation for influenza A (H1N1)v infection in children. Acta Paediatr. 99(Suppl. 462), 85, PP091 (2010).
90. Andrews N, Waight P, Yung C-F, Miller E. Age-specific effectiveness of an oil-in-water adjuvanted pandemic (H1N1) 2009 vaccine against confirmed infection in high risk groups in England. J. Infect. Dis. 203(1), 32-39 (2011). This study is a postpandemic evaluation of a AS03-adjuvanted H1N1 vaccine, showing effectiveness but also age group differences.
91. Van Buynder PG, Dhaliwal JK, Van Buynder JL et al. Protective effect of single-dose adjuvanted pandemic influenza vaccine in children. Influenza Other Respi. Viruses 4(4), 171-178 (2010).
92. Walker WT, Faust SN. Monovalent inactivated split-virion AS03-adjuvanted pandemic influenza A (H1N1) vaccine. Expert Rev. Vaccines 9(12), 1385-1398 (2010).
93. Rümke HC, Bayas J-M, de Juanes J-R et al. Safety and reactogenicity profile of an adjuvanted H5N1 pandemic candidate vaccine in adults within a Phase III safety trial. Vaccine 26(19), 2378-2388 (2008).
94. Ballester A, Garces-Sanchez M, Planelles Cantarino MV et al. Pediatric safety eEvaluation of an AS-adjuvanted H5N1 prepandemic candidate vaccine in children Aged 3-9 Years: a Phase II study. Presented at: 48th ICAAC. Washington, DC, USA, 25-28 October 2008.
95. A-adjuvanted H1N1 2009 pandemic influenza vaccine in adults in Japan. Hum. Vaccines 6(11), 888-893 (2010).
96. A-adjuvanted 2009 influenza A (H1N1) vaccines: a randomised, multicentre, age-stratified, head-to-head trial. Lancet Infect. Dis. 11(2), 91-101 (2011).
97. Garcia-Sicilia J, Gillard P, Carmona A et al. Immunogenicity and safety of AS03-adjuvanted H1N1 pandemic vaccines in children and adolescents. Vaccine 29(26), 4353-4361 (2011).
98. Tavares F, NazarethI, Sawchik Monegal J, Kolte I, Vertraeten T, Bauchau V. Active safety follow up of a cohort of pregnant women vaccinated withan AS03-adjuvanted split virion H1N1 (2009) pandemic influenza vaccine. Presented at: XIII International Symposium on Respiratory Viral Infections. Rome, Italy, 13-16 March 2011.
99. Dauvilliers Y, Montplaisir J, Cochen V et al. Post-H1N1 narcolepsy-cataplexy. Sleep 33(11), 1428-1430 (2010).
100. Han F, Lin L, Warby SC et al. Narcolepsy onset isseasonal and increased following the 2009 H1N1 pandemic in China. Ann. Neurol. 70(3), 410-417 (2011).
101. Morel S, Didierlaurent A, Bourguignon P et al. Adjuvant System AS03 containing a-tocopherol modulates innate immune response and leads to improved adaptive immunity. Vaccine 29(13), 2461-2473 (2011). This study is a detailed description of the mode of action of AS03 in nonclinical models.
102. Hayden MS, West AP, Ghosh S. NF-κB and the immune response. Oncogene 25(51), 6758-6780 (2006).
103. Morel S, Didierlaurent A, Bourguignon P et al. Link between innate responses and the enhanced adaptive response induced by novel adjuvanted vaccines: insight into AS03's mode of action. Presented at: 8th International Conference on Innate Immunity. Crete, Greece, 15-20 June 2011.
104. Malherbe L, Mark L, Fazilleau N, McHeyzer-Williams LJ, McHeyzer-Williams MG. Vaccine adjuvants alter TCR-based selection thresholds. Immunity 28(5), 698-709 (2008).
105. World HealthOrganization. World malaria report 2010. (2010). www.who.int/malaria/world-malaria-report-2010/worldmalariareport2010.pdf (Accessed 30 January 2012)
106. UNAIDS World HealthOrganization. AIDS epidemic update. (2009). www.unaids.org/en/media/unaids/contentassets/dataimport/pub/report/2009/ jc1700-epi-update-2009-en.pdf (Accessed 31 January 2012)
107. Food and Drug Administration. Guidance for industry: clinical data needed to support the licensure of pandemic influenza vaccines. (2009). www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatory Information/Guidances/Vaccines/ucm074786.htm (Accessed 30 January 2012)
108. Committee for human medicinal products (CHMP). Guideline on influenza vaccines prepared from viruses withthe potential to cause a pandemic and intended for use outside of the core dossier content (2009). www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2009/09/ WC500003872.pdf (Accessed 30 January 2012)
109. European Medicines Agency. Questions and answers on the review of Pandemrix influenza vaccine (H1N1) (split virion, inactivated, adjuvanted) A/California/7/2009 (H1N1)v like strain (X-179A). (2011). www.ema.europa.eu/ docs/en-GB/document-library/Medicine-QA/2011/07/WC500109183.pdf